TY  - JOUR
TI  - Effect of Adjuvant Chemotherapy/Chemoradiotherapy on  Disease-Free Survival in Gastric Cancer
AB  - Objectives: The main treatment for gastric cancer is surgery. The high recurrence and metastasis rates indicate the necessity of neoadjuvant/adjuvant treatments. Our aim was to evaluate the effects of adjuvant therapy on disease-free survival (DFS) and prognostic factors with gastric cancer patients. Methods: Gastric cancer patients who were operated between 2015-2021 were evaluated retrospectively. Clinical, pathological, surgical and therapeutic features of patients were examined. Prognostic factors, Hemoglobin Albumin  Lymphocyte, Platelet Score (HALP) and metastatic lymph node ratio (MLNR) of patients were examined. 1-5 year survival rate were calculated. Results: Adjuvant chemotherapy was applied to fifty-nine patients and adjuvant chemoradiotherapy was applied to sixtyeight patients. There was no difference in demographic and clinical characteristics between patient groups who received chemotherapy and chemoradiotherapy. DFS was 34 and 52 months with chemotherapy and chemoradiotherapy patients respectively (p=0.161). High MLNR levels of patients was poor prognostic factor. HALP score did not affect prognosis. 5-years overall survival rate was better in chemoradiotherapy group, but the difference was not statistically significant  (41.2% vs 50.9%, p=0.216). Conclusion: There was no difference in survival between patients who received adjuvant chemotherapy and chemoradiotherapy. MLNR of patients may be considered as a prognostic marker for gastric cancer patients with high nodal involvement.
AU  - ALANDAĞ, Celal
AU  - yüce, elif
AU  - KARAMAN, ELANUR
DO  - 10.14744/ejmi.2022.22190
PY  - 2022
JO  - Eurasian Journal of Medical Investigation
VL  - 6
IS  - 4
SN  - 2602-3164
SP  - 497
EP  - 505
DB  - TRDizin
UR  - http://search/yayin/detay/1133798
ER  -